Publications
137
Citations
2,796
Est. group size
~33
Recurring co-author estimate
Active years
24
Publishing since 2003
Patrick Schnell works in biostatistics, developing statistical methods for analyzing clinical trial and medical records data, with a particular focus on identifying patient subgroups who benefit most from treatments (a process called subgroup identification). Much of the applied work involves cancer clinical trials, including studies of drugs like palbociclib for breast cancer, as well as collaborations on COVID-19 treatment trials and cognitive screening research.
Publication output has generally grown over the past decade, rising from single digits in 2017-2018 to a peak of over 20 papers in 2024, with some year-to-year fluctuation.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Bayesian data augmentation for recurrent events under intermittent assessment in overlapping intervals with applications to EMR data
The Annals of Applied Statistics · 2025
- Investigating Stability in Subgroup Identification for Stratified Medicine
Pharmaceutical Statistics · 2024
- Stabilizing Backpropagation Through Time to Learn Complex Physics
arXiv (Cornell University) · 2024
- Bayesian Shrinkage Estimation of Credible Subgroups for Count Data with Excess Zeros
Statistics in Biopharmaceutical Research · 2024
- Controlling the false-discovery rate when identifying the subgroup benefiting from treatment
Clinical Trials · 2023
- Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)
Scientific Reports · 2022
- A Principal Stratification Approach to Estimating the Effect of Continuing Treatment after Observing Early Outcomes
Journal of the Royal Statistical Society Series C (Applied Statistics) · 2022
- Half-Inverse Gradients for Physical Deep Learning
arXiv (Cornell University) · 2022
- Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up
The Oncologist · 2021
- Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
The Breast · 2021
- Real‐World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men
Clinical Pharmacology & Therapeutics · 2021
- Alleviating confounding in spatio-temporal areal models with an application on crimes against women in India
Statistical Modelling · 2021
- Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3
The Oncologist · 2021
- Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
JNCI Cancer Spectrum · 2021
- Institutional experience on cognitive screening at the Medicare Annual Wellness Visit
Alzheimer s & Dementia · 2021
- Journal of Clinical Oncology×10
- arXiv (Cornell University)×7
- Current Developments in Nutrition×6
- Cancer Research×6
- Journal of the Academy of Nutrition and Dietetics×5
- Preeti Sudheendra
Medicine · The Ohio State University
- Sagar Sardesai
Medicine · The Ohio State University
- Robert Wesolowski
Medicine · The Ohio State University
- Gilbert Bader
Medicine · The Ohio State University
- Sarah Khan
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile